Division Head, at University of Basel, Switzerland.
Niklaus Daniel Labhardt is a highly respected physician and researcher specializing in infectious diseases, tropical medicine, and clinical epidemiology. Currently, he serves as a Full Professor and Division Head of Clinical Epidemiology at the University of Basel, as well as the Department Head of Clinical Research. With over two decades of professional experience, Dr. Labhardt has made significant contributions to improving HIV care in resource-limited settings and advancing global health initiatives. His work spans clinical practice, teaching, and mentorship, with active involvement in supervising Ph.D. and M.D. students. As a thought leader, he collaborates with global organizations and serves on various advisory boards. Dr. Labhardt’s extensive publication record and accolades, such as the Pfizer Research Prize, reflect his commitment to innovative healthcare solutions.
Professional Profile
Scopus
ORCID
Google Scholar
Education 🎓
- 2020: Specialist in Infectious Diseases (FMH)
- 2019: SNSF Eccellenza Professorship, Swiss National Science Foundation
- 2018: Assistant Professor at the University of Basel (“Habilitation”)
- 2017: Specialist in Tropical Medicine and Traveller’s Health (FMH)
- 2015: Specialist in General Internal Medicine (FMH)
- 2010: Master of Advanced Studies in International Health (MIH), Swiss TPH and Antwerp Institute of Tropical Medicine
- 2005: Medical Doctoral Thesis (MD), University of Basel
- 2004: Physician Diploma, University of Basel
His robust academic foundation reflects his interdisciplinary expertise, equipping him to address challenges in global and clinical health.
Experience 🏥
Dr. Labhardt has held several impactful roles throughout his career:
- Since 2022: Full Professor & Division Head, Clinical Epidemiology, University of Basel.
- 2017-2022: Senior Physician at the University Hospital Basel, leading research on infectious diseases.
- 2010-2012: Project Manager, SolidarMed, Lesotho, spearheading HIV and TB care projects.
- 2005-2016: Physician and Advisor in Switzerland and Cameroon under various collaborations.
- 2014-Present: Research Group Leader at the Swiss Tropical and Public Health Institute.
His multifaceted career showcases a balance between clinical excellence, academic leadership, and impactful global health projects.
Research Interests 🔬
Dr. Labhardt’s research focuses on:
- HIV and TB Care: Exploring innovative models for HIV treatment initiation and care delivery in resource-limited settings.
- Global Health Systems: Strengthening collaboration networks to tackle emerging infectious diseases.
- Clinical Epidemiology: Developing cost-effective, scalable healthcare solutions.
- Randomized Trials: Investigating effective interventions for chronic diseases in underserved regions.
His work has significantly influenced global healthcare policy and clinical practices, especially in Africa and low-income countries.
Awards 🏆
Dr. Labhardt has received numerous prestigious awards, including:
- 2019: Pfizer Research Prize in Infectiology, Rheumatology, and Immunology.
- 2018: First Prize at SSI/SAFE-ID Awards for Clinical Research in Infectious Diseases.
These recognitions underscore his exceptional contributions to clinical research and infectious disease management.
Top Notes Publications đź“š
Below are selected publications with hyperlinks:
- Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment
- Authors: Labhardt ND, et al.
- Journal: Clinical Infectious Diseases
- Year: 2023
- Volume: 77
- Issue: 8
- Pages: 1176–1184
- Abstract: This study investigates the clinical and programmatic outcomes of same-day HIV treatment initiation. It evaluates whether offering antiretroviral therapy (ART) immediately after diagnosis enhances patient retention and viral suppression rates compared to standard deferred treatment initiation.
- Link: Access the paper here
- Head-to-Head Comparison of Nasal and Nasopharyngeal Sampling Using SARS-CoV-2 Rapid Antigen Testing in Lesotho
- Authors: Labhardt ND, et al.
- Journal: PLoS One
- Year: 2023
- Volume: 18
- Issue: 3
- Article: e0278653
- Abstract: This research compares the accuracy, patient comfort, and feasibility of nasal swab sampling versus nasopharyngeal swabs for SARS-CoV-2 rapid antigen tests in a resource-limited setting. The findings highlight the potential of less invasive testing methods in improving accessibility and compliance.
- Link: Access the paper here
- Post-Exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for SARS-CoV-2
- Authors: Labhardt ND, et al.
- Journal: EClinicalMedicine
- Year: 2021
- Volume: 42
- Article: 101188
- Abstract: This study assesses the efficacy of lopinavir-ritonavir as a post-exposure prophylaxis measure for SARS-CoV-2 compared to a standard surveillance approach. It provides insights into the effectiveness and limitations of repurposed antiviral agents in mitigating COVID-19 transmission.
- Link: Access the paper here
Conclusion
Niklaus Daniel Labhardt is an exceptional candidate for the Best Researcher Award. His extensive contributions to infectious diseases, clinical epidemiology, and global health, coupled with his leadership in academia and research, position him as a leading figure in his field. Addressing areas like public engagement and expanding research domains could further amplify his already impressive impact. Overall, his profile, achievements, and global contributions strongly align with the award’s criteria, making him a highly deserving nominee.